ELTP chugs along and if you've followed along in the message boards, my deepest and most sincere condolences. Best to let your investment breath, which also isn't to say not to demand the best from the CEO. You're weak if ya do and weak if ya don't so worry not. Elite has a ton going for it, they just are not the PR machine it used to be so wait for it. When stupid fucktards make comments like "Why did it take 6 months to address the CRL I mean with expedited
review it should have only take 3 months. What was Elite doing all that
time?" you don't need to take time out of your day to respond, there is no need to educate, the fucktards are going to be fucktards when you let em. I find the message boards, particularly on iHub, to have lost serious luster and when you just have a bunch of folks pushing against something that may or may not - at the end of the day facts good or bad will surface with out the hyperbole. In a perfect world that is..
PR like the following don't say much of anything, so what. If you can't draw as much based upon a first glance over of the PR maybe you need to be sucker punched anyway!
Elite Provides Update On SequestOx™ New Drug Application
NORTHVALE, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the "FDA") on December 21, 2016 for an end-of-review meeting to discuss steps that Elite can take to obtain approval of SequestOx™. Based on the FDA response, the Company believes there is a clear path forward to address the issues cited in the July 14th Complete Response Letter ("CRL"). The FDA will provide minutes of the meeting by the end of January and the Company will issue a further update at that time.
SequestOx™ (oxycodone hydrochloride and naltrexone hydrochloride) is Elite's investigational abuse-deterrent opioid candidate for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. The proposed plan submitted by the Company addresses items cited in the CRL dated July 14, 2016 for the New Drug Application (the "NDA") for SequestOx™.
"We are extremely pleased that there is a path forward to seek FDA approval of SequestOx™," said Nasrat Hakim, President and CEO of Elite. "Based on the guidance received from the agency, Elite will begin to execute the proposed plan immediately."
So you see, no need for gratuitous expletives, ad hominem attacks, or other displays of internet weakness. Push for the best, demand the best from your CEO, work together in the boards for a better day by using the facts, yes especially those hard to swallow facts. Those come in handy and then find your trends or just sit back and show confidence in where your money is sitting.
PR like the following don't say much of anything, so what. If you can't draw as much based upon a first glance over of the PR maybe you need to be sucker punched anyway!
anyway! Elite Provides Update On SequestOx™ New Drug Application
NORTHVALE, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the "FDA") on December 21, 2016 for an end-of-review meeting to discuss steps that Elite can take to obtain approval of SequestOx™. Based on the FDA response, the Company believes there is a clear path forward to address the issues cited in the July 14th Complete Response Letter ("CRL"). The FDA will provide minutes of the meeting by the end of January and the Company will issue a further update at that time.
SequestOx™ (oxycodone hydrochloride and naltrexone hydrochloride) is Elite's investigational abuse-deterrent opioid candidate for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. The proposed plan submitted by the Company addresses items cited in the CRL dated July 14, 2016 for the New Drug Application (the "NDA") for SequestOx™.
"We are extremely pleased that there is a path forward to seek FDA approval of SequestOx™," said Nasrat Hakim, President and CEO of Elite. "Based on the guidance received from the agency, Elite will begin to execute the proposed plan immediately."
So you see, no need for gratuitous expletives, ad hominem attacks, or other displays of internet weakness. Push for the best, demand the best from your CEO, work together in the boards for a better day by using the facts, yes especially those hard to swallow facts. Those come in handy and then find your trends or just sit back and show confidence in where your money is sitting.
No comments:
Post a Comment